Krystal Biotech, Inc. (KRYS) Operating Margin
- Operating margin · 12 months: Value 44.89%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 44.89% | Operating income / revenue. Period ending 2026-06-30. $197.75M ÷ $440.48M × 100 ≈ 44.89% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 197.75M USD | Operating Income (Loss) |
| Revenue | 440.48M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 59.23M USD | Research and Development Expense |
| Selling, general and administration | 159.89M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $197.75M | $440.48M | (m) | $59.23M | $159.89M | 44.89% |
| 2026-03-31 | $178.73M | $417.30M | (m) | $59.12M | $155.11M | 42.83% |
| 2025-12-31 | $161.29M | $389.13M | (m) | $58.05M | $146.74M | 41.45% |
| 2025-09-30 | $158.35M | $373.16M | (m) | $56.77M | $136.64M | 42.43% |
| 2025-06-30 | $139.29M | $359.20M | (m) | $55.70M | $127.88M | 38.78% |
| 2025-03-31 | $108.56M | $333.45M | (m) | $56.87M | $120.35M | 32.56% |
| 2024-12-31 | $65.69M | $290.51M | (m) | $53.57M | $113.69M | 22.61% |
| 2024-09-30 | $27.45M | $241.52M | (m) | $51.42M | (m) | 11.37% |
| 2024-06-30 | $-20.97M | $166.23M | (m) | $48.54M | (m) | -12.62% |
| 2024-03-31 | $-67.59M | $95.95M | (m) | $45.10M | (m) | -70.44% |
| 2023-12-31 | $-109.73M | $50.70M | (m) | $46.43M | (m) | -216.43% |
| 2023-09-30 | $-147.64M | (m) | (m) | $45.80M | (m) | (m) |
| 2023-06-30 | $-153.09M | (m) | (m) | $46.69M | (m) | (m) |
| 2023-03-31 | $-143.80M | (m) | (m) | $45.44M | (m) | (m) |
| 2022-12-31 | $-145.20M | (m) | (m) | $42.46M | (m) | (m) |
| 2022-09-30 | $-132.30M | (m) | (m) | $40.73M | (m) | (m) |
| 2022-06-30 | $-116.50M | (m) | (m) | $35.29M | (m) | (m) |
| 2022-03-31 | $-104.14M | (m) | (m) | $31.00M | (m) | (m) |
| 2021-12-31 | $-68.28M | (m) | (m) | $27.88M | (m) | (m) |
| 2021-09-30 | $-56.82M | (m) | (m) | $24.55M | (m) | (m) |
| 2021-06-30 | $-50.85M | (m) | (m) | $23.57M | (m) | (m) |
| 2021-03-31 | $-41.41M | (m) | (m) | $20.61M | (m) | (m) |
| 2020-12-31 | $-33.00M | (m) | (m) | $17.94M | (m) | (m) |
| 2020-09-30 | $-28.73M | (m) | (m) | $16.61M | (m) | (m) |
| 2020-06-30 | $-24.39M | (m) | (m) | $15.40M | (m) | (m) |
| 2020-03-31 | $-23.33M | (m) | (m) | $15.97M | (m) | (m) |
| 2019-12-31 | $-22.08M | (m) | (m) | $15.62M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-11.92M | (m) | (m) | $7.76M | (m) | (m) |
| 2018-09-30 | $-9.20M | (m) | (m) | $6.05M | (m) | (m) |
| 2018-06-30 | $-8.32M | (m) | (m) | $5.49M | (m) | (m) |
| 2018-03-31 | $-6.58M | (m) | (m) | $4.41M | (m) | (m) |
| 2017-12-31 | $-4.77M | (m) | (m) | $3.21M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-1.14M | (m) | (m) | $741.00K | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |